RKL Wealth Management LLC Has $249,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

RKL Wealth Management LLC lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 29.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 953 shares of the medical research company’s stock after selling 400 shares during the period. RKL Wealth Management LLC’s holdings in Amgen were worth $249,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of AMGN. Swedbank AB boosted its position in Amgen by 1.1% during the third quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after purchasing an additional 5,751 shares during the period. Capital Performance Advisors LLP bought a new position in Amgen during the third quarter worth $25,000. Leavell Investment Management Inc. boosted its position in Amgen by 42.8% during the third quarter. Leavell Investment Management Inc. now owns 17,756 shares of the medical research company’s stock worth $5,721,000 after purchasing an additional 5,325 shares during the period. CWA Asset Management Group LLC bought a new position in Amgen during the third quarter worth $1,719,000. Finally, Windward Capital Management Co. CA boosted its position in Amgen by 2.6% during the third quarter. Windward Capital Management Co. CA now owns 22,239 shares of the medical research company’s stock worth $7,166,000 after purchasing an additional 556 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In other news, EVP David M. Reese sold 8,711 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total value of $2,554,239.42. Following the completion of the transaction, the executive vice president now owns 62,147 shares of the company’s stock, valued at $18,222,743.34. This represents a 12.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 over the last quarter. 0.69% of the stock is owned by company insiders.

Amgen Stock Up 2.2 %

Shares of NASDAQ AMGN opened at $324.86 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The company has a market cap of $174.52 billion, a price-to-earnings ratio of 43.03, a PEG ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock has a 50-day moving average price of $286.14 and a two-hundred day moving average price of $299.69.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s payout ratio is 126.09%.

Analyst Upgrades and Downgrades

A number of research firms have commented on AMGN. Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 price objective on shares of Amgen in a research report on Thursday, January 2nd. Leerink Partners reduced their price objective on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 target price on shares of Amgen in a research report on Friday, January 24th. Bank of America boosted their target price on shares of Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a research report on Wednesday. Finally, Wolfe Research initiated coverage on shares of Amgen in a research report on Friday, November 15th. They issued a “peer perform” rating for the company. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $314.95.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.